Risk factors for recurrent venous thromboembolism: a real-world analysis

被引:4
作者
Fu, Alex Z. [1 ,2 ]
Feng, Xue [1 ]
Ashton, Veronica [1 ]
Kharat, Akshay [1 ]
机构
[1] Janssen Sci Affairs LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA
[2] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
关键词
claims database; cohort study; recurrence; risk factors; venous thromboembolism; CHRONIC KIDNEY-DISEASE; DEEP-VEIN THROMBOSIS; CANCER; THERAPY; VTE; ANTICOAGULATION; PREVENTION; MANAGEMENT; BURDEN;
D O I
10.1097/MBC.0000000000001140
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study was conducted in patients treated for initial venous thromboembolism (VTE) for approximately 6 months to enhance understanding of the risk factors to inform clinical decision-making about long-term anticoagulation therapy. This retrospective cohort study was conducted using a large administrative claims database in the United States. A Cox proportional hazards model was used to examine demographic and clinical characteristics associated with recurrent VTE. A total of 13 831 patients had an index VTE event, and recurrent VTE occurred in 844 (6.1%) of these patients over a median follow-up of 22.8 months. Baseline comorbidities of arrhythmia, congestive heart failure, and chronic kidney disease were significantly associated with recurrent VTE. During the period of anticoagulation treatment after the index VTE, use of antidepressants was associated with an increased risk of recurrent VTE, whereas use of antibiotics and major surgery were associated with a decreased risk. In the 6 months prior to index VTE, anti-inflammatory agents and major surgery were associated with a decreased risk of recurrent VTE. The type of index VTE was also significantly associated with recurrent VTE, with an increased risk observed in patients with pulmonary embolism (PE) alone or PE with deep vein thrombosis (DVT) versus DVT alone. This real-world analysis identified baseline comorbidities, medications, and index VTE type to be factors predictive of recurrent VTE among patients treated for index VTE for approximately 6 months. Consideration of these factors may assist in the identification of patients who may benefit from extended anticoagulant therapy.
引用
收藏
页码:301 / 309
页数:9
相关论文
共 38 条
[1]   Risk factors for venous thromboembolism [J].
Anderson, FA ;
Spencer, FA .
CIRCULATION, 2003, 107 :I9-I16
[2]   Cancer-associated venous thromboembolism: Burden, mechanisms, and management [J].
Ay, Cihan ;
Pabinger, Ingrid ;
Cohen, Alexander T. .
THROMBOSIS AND HAEMOSTASIS, 2017, 117 (02) :219-230
[3]   Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis [J].
Baglin, T. ;
Douketis, J. ;
Tosetto, A. ;
Marcucci, M. ;
Cushman, M. ;
Kyrle, P. ;
Palareti, G. ;
Poli, D. ;
Tait, R. C. ;
Iorio, A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (11) :2436-2442
[4]   Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation [J].
Barnes, Geoffrey D. ;
Kanthi, Yogendra ;
Froehlich, James B. .
VASCULAR MEDICINE, 2015, 20 (02) :143-152
[5]   Lifetime Risk of Venous Thromboembolism in Two Cohort Studies [J].
Bell, Elizabeth J. ;
Lutsey, Pamela L. ;
Basu, Saonli ;
Cushman, Mary ;
Heckbert, Susan R. ;
Lloyd-Jones, Donald M. ;
Folsom, Aaron R. .
AMERICAN JOURNAL OF MEDICINE, 2016, 129 (03) :339.e19-339.e26
[6]  
Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI [10.1161/CIR.0000000000000659, 10.1161/CIR.0000000000000746]
[7]   The Value of Family History as a Risk Indicator for Venous Thrombosis [J].
Bezemer, Irene D. ;
van der Meer, Felix J. M. ;
Eikenboom, Jeroen C. J. ;
Rosendaal, Frits R. ;
Doggen, Carine J. M. .
ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (06) :610-615
[8]   Economic burden of recurrent venous thromboembolism: Analysis from a US hospital perspective [J].
Casciano, Julian P. ;
Dotiwala, Zenobia ;
Kemp, Robert ;
Li, Chenghui ;
Cai, Jennifer ;
Preblick, Ronald .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (04) :291-300
[9]  
Chang HM, 2017, J AM COLL CARDIOL, V70, P2552, DOI [10.1016/j.jacc.2017.09.1095, 10.1016/j.jacc.2017.09.1096]
[10]   Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data [J].
Costa, Olivia S. ;
Beyer-Westendorf, Jan ;
Ashton, Veronica ;
Milentijevic, Dejan ;
Moore, Kenneth Todd ;
Bunz, Thomas J. ;
Coleman, Craig, I .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2021, 51 (02) :349-358